Literature DB >> 12782019

Transduction of dominant negative ATF-1 suppresses the pX gene expression in joint fibroblastic cells derived from HTLV-I transgenic rats.

Akihiro Ishizu1, Takahiro Tsuji, Asami Abe, Saori Saito, Toshiyuki Takahashi, Hitoshi Ikeda, Daniel Meruelo, Takashi Yoshiki.   

Abstract

Tax (p40Tax) encoded by the env-pX gene of human T-cell leukemia virus type I (HTLV-I) interacts with cyclic adenosine-3',5'-monophosphate response element binding protein/activation transcription factor 1 (CREB/ATF-1) transcription factors of host cells and activates the viral long terminal repeat (LTR) promoter. This molecular interaction induces augmentation of viral gene expression and may result in development of HTLV-I-associated diseases, including adult T-cell leukemia, HTLV-I associated myelopathy/tropical spastic paraparesis, and HTLV-I uveitis. To inhibit this pathway, a dominant negative molecule of ATF-1, ATF-1DN, was used. We transduced ATF-1DN into joint fibroblastic cells derived from transgenic rats carrying the LTR-env-pX-LTR gene of HTLV-I, using the Sindbis virus-based vectors. Expression of the pX gene in cells transduced with ATF-1DN was lower than that in cells with control transfection. A possible application of ATF-1DN to suppress viral gene expression in HTLV-I infected cells can be considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782019     DOI: 10.1016/s0014-4800(02)00019-9

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  1 in total

1.  Bone marrow cells carrying the env-pX transgene play a role in the severity but not prolongation of arthritis in human T-cell leukaemia virus type-I transgenic rats: a possible role of articular tissues carrying the transgene in the prolongation of arthritis.

Authors:  Asami Abe; Akihiro Ishizu; Hitoshi Ikeda; Hiroko Hayase; Takahiro Tsuji; Yukiko Miyatake; Muneharu Tsuji; Kazunori Fugo; Toshiaki Sugaya; Masato Higuchi; Takeo Matsuno; Takashi Yoshiki
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.